Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Debt (2022 - 2025)

Historic Total Debt for Cue Biopharma (CUE) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Cue Biopharma's Total Debt fell 6906.91% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 6906.91%. This contributed to the annual value of $4.3 million for FY2024, which is 4693.2% down from last year.
  • As of Q3 2025, Cue Biopharma's Total Debt stood at $1.6 million, which was down 6906.91% from $2.6 million recorded in Q2 2025.
  • Cue Biopharma's Total Debt's 5-year high stood at $10.1 million during Q2 2023, with a 5-year trough of $1.6 million in Q3 2025.
  • Moreover, its 4-year median value for Total Debt was $8.2 million (2023), whereas its average is $7.2 million.
  • In the last 5 years, Cue Biopharma's Total Debt surged by 219.04% in 2023 and then tumbled by 6906.91% in 2025.
  • Quarter analysis of 4 years shows Cue Biopharma's Total Debt stood at $10.0 million in 2022, then fell by 18.33% to $8.2 million in 2023, then tumbled by 46.93% to $4.3 million in 2024, then plummeted by 61.97% to $1.6 million in 2025.
  • Its Total Debt was $1.6 million in Q3 2025, compared to $2.6 million in Q2 2025 and $3.4 million in Q1 2025.